MAM
Patanjali launches Coronil drug for Covid2019
MUMBAI: Baba Ramdev's Patanjali launched an ayurvedic medicine for treating Covid2019 today at Patanjali Yogpeeth in Haridwar.
Earlier this month, Patanjali Ayurved managing director Acharya Balkrishna had claimed that an ayurvedic medicine developed by the company has been able to cure Covid2019 patients within five to 14 days. Patanjali Ayurved Ltd MD Acharya Balkrishna had announced the launch on Twitter on Monday evening.
"We've prepared the first ayurvedic clinically-controlled, research, evidence and trial based medicine for Covid2019. We conducted a clinical case study and clinical controlled trial and found 69 per cent patients recovered in three days and 100 per cent patients recovered in seven days," said Ramdev.
Ramdev claims that there has been 0 per cent death rate and 100 per cent recovery rate has been observed, around 69 per cent of the people recovered within six days. 100 per cent of the people has recovered thanks to the medicine made by it.
He also stated that they have done every research.
"We appointed a team of scientists after Covid2019 outbreak. Firstly, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results," Balkrishna said at the launch.
"After taking our medicine, patients recovered in five to 14 days and then tested negative. So, we can say the cure for Covid2019 is possible through Ayurveda. We are performing controlled clinical trials only. In the next four to five days, evidence and data will be released by us," he added.
The medicine has been manufactured by Haridwar’s Divya Pharmacy and Patanjali Ayurved Ltd in Haridwar, based on a joint research by Patanjali Research Institute in Haridwar and the National Institute of Medical Science, Jaipur.
Brands
Jubilant FoodWorks faces Rs 47.5 crore GST demand, plans appeal
Tax authorities flag alleged misclassification of restaurant services
MUMBAI:Â Jubilant FoodWorks Limited has landed in a tax tussle after receiving a GST demand of Rs 47.5 crore from the office of the additional commissioner of CGST and central excise in Thane, Maharashtra.
The order, issued under the provisions of the Central Goods and Services Tax Act, 2017, relates to an alleged incorrect classification of certain services under the category of restaurant services. According to the tax authorities, this classification resulted in a short payment of goods and services tax for the period between the financial years 2019-20 and 2021-22.
The demand includes Rs 47.5 crore in GST along with an equal amount as penalty, in addition to applicable interest. The order was received by the company on March 13, 2026.
In a regulatory filing to the BSE Limited and the National Stock Exchange of India Limited, the company said it disagrees with the order and believes its arguments were not adequately considered.
The company is preparing to challenge the decision and plans to file an appeal. It added that once the redressal process is complete, the demand is likely to be dropped.
Despite the sizeable figure attached to the notice, the company said it does not expect any material impact on its financials, operations or other activities.
The disclosure was signed by Suman Hegde, EVP and chief financial officer, who confirmed that the company received the order at 19:06 IST on March 13 and has already initiated steps to contest it.
The development places the quick service restaurant major in the middle of a tax debate that could hinge on how certain restaurant-linked services are classified under GST rules. For now, the company appears ready to take the matter from the tax office to the appeals desk.
